Brief: Arca Biopharma Announces FDA Approval Of IND Application For Ab201 As A Potential Treatment For Covid-19
07/10/2020 13:43
Oct 7 (Reuters) - ARCA Biopharma Inc ABIO.O :
* ARCA BIOPHARMA ANNOUNCES FDA APPROVAL OF IND APPLICATION
FOR
AB201 AS A POTENTIAL TREATMENT FOR COVID-19
* ARCA BIOPHARMA INC - INITIATION OF PHASE 2B CLINICAL TRIAL
ANTICIPATED IN Q4 2020
* ARCA BIOPHARMA INC - TRIAL TO ENROLL APPROXIMATELY 100
PATIENTS
HOSPITALIZED WITH COVID-19
* ARCA BIOPHARMA INC - STUDY TOPLINE DATA ANTICIPATED Q2
2021
Source text for Eikon: ID:nGNX8fLfT0
Further company coverage: ABIO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oruka Therapeutics
See all newsOruka falls after reporting mid-stage data for psoriasis drug
Brief: Oruka Therapeutics Announces Positive Week 28 Data For Orka-001 From The Ongoing Everlast-A Trial Showing Deepening Of Responses Without Additional Dosing
Brief: Oruka Therapeutics Appoints Todd Edwards As Chief Commercial Officer
U.S. RESEARCH ROUNDUP-Accendra Health, Celestica, Sionna Therapeutics
Oruka Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary